康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的临床研究

目的　观察玻璃体内注射康柏西普治疗视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）继发黄斑水肿的疗效。方法　回顾性病例系列研究。回顾我院确诊为BRVO继发黄斑水肿行玻璃体内注射康柏西普患者31例31眼；随访 7.9~12.8 (9.53±1.20)个月。对比治疗前后最佳矫正视力（best corrected visual acuity，BCVA）、黄斑中心视网膜厚度（central macular thickness，CMT）及黄斑中心凹厚度（macular thickness，MT）的变化，记录与药物和治疗方式相关的并发症发生情况。结果　治疗前BCVA为（0.72±0.37）LogMAR，末次复查BCVA提高至（0.46±0.38）LogMAR，治疗前后差异有统计学意义（t=4.24，P<0.001）。12例患者视力得到了提高，19例患者视力维持稳定。注药前CMT为（461.16±146.20）μm，MT为（571.58±242.27）μm；末次复查CMT下降为（264.68±90.41）μm，MT下降为（272.29±188.54）μm，治疗前后差异均有统计学意义（CMT:t=6.24，P<0.001；MT:t=5.42，P<0.001）。所有患者随访期间均未见玻璃体出血、视网膜脱离、持续高眼压和眼内炎等并发症发生。结论　玻璃体内注射康柏西普治疗BRVO继发黄斑水肿有一定疗效，可以改善视力、减轻黄斑水肿。

Clinical outcomes of intravitreal Conbercept injection for macular edema secondary to branch retinal vein occlusion

Objective　To observe the efficacy of intravitreal Conbercept injectionsinmacular edema secondary to branch retinal vein occlusion (BRVO).Methods　Retrospective case series study was conducted in 31 eyes of 31 patients with BRVO who received intravitreal injections of Conbercept and the data were collected in this study.The follow-up time was 7.9 to 12.8 months,with the average of (9.53±1.20)months.The best corrected visual acuity (BCVA),central macular thickness (CMT) and macular thickness (MT) before and after therapy were compared.And complications associated with medicine and treatment modality were also recorded during the follow-up.Results　The BCVA before therapy was (0.72±0.37)LogMAR and increased to (0.46±0.38)LogMAR at the last follow-up,which showed a statistical difference（t=4.24，P<0.001）.Furthermore,the visual acuity of 12 patients got improved and 17 patients kept stable.The CMT and MT before therapy were (461.16±146.20) μm and (571.58±242.27)μm,respectively.At the last follow-up,the CMT and MT decreased to (264.68±90.41)μm and (272.29±188.54)μm,respectively.There were significant statistical difference for both CMT and MT before and after surgery（CMT:t=6.24，P<0.001； MT:t=5.42，P<0.001）.Finally,no severe complication occurred during the follow-up,such as vitreous hemorrhage,retinal detachment,intraocular hypertension and endophthalmitis.Conclusion　Intravitreal injection of Conbercept shows a certain curative effect in macular edema secondary to BRVO,which can not only improve visual acuity but also reduce macular thickness.